L. Lausen, L. Lundbo, and T. Benfield, Hepatitis C virus infection in the human immunodeficiency virus infected patient, World Journal of Gastroenterology, vol.20, issue.34, pp.12132-12175, 2014.
DOI : 10.3748/wjg.v20.i34.12132

E. Operskalski and A. Kovacs, HIV/HCV Co-infection: Pathogenesis, Clinical Complications, Treatment, and New Therapeutic Technologies, Current HIV/AIDS Reports, vol.49, issue.3, pp.12-22, 2011.
DOI : 10.1007/s11904-010-0071-3

M. Hanafiah, K. Groeger, J. Flaxman, A. Wiersma, and S. , Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence, Hepatology, vol.29, issue.Suppl
DOI : 10.1002/hep.26141

L. Peters and M. Klein, Epidemiology of hepatitis C virus in HIV-infected patients, Current Opinion in HIV and AIDS, vol.10, issue.5, pp.297-302, 2015.
DOI : 10.1097/COH.0000000000000183

V. Rao, N. Johari, P. Du-cros, J. Messina, N. Ford et al., Hepatitis C seroprevalence and HIV co-infection in sub-Saharan Africa: a systematic review and meta-analysis, The Lancet Infectious Diseases, vol.15, issue.7, pp.819-824, 2015.
DOI : 10.1016/S1473-3099(15)00006-7

P. Matthews, A. Geretti, P. Goulder, and P. Klenerman, Epidemiology and impact of HIV coinfection with Hepatitis B and Hepatitis C viruses in Sub-Saharan Africa, Journal of Clinical Virology, vol.61, issue.1, pp.20-33, 2014.
DOI : 10.1016/j.jcv.2014.05.018

D. Dhumeaux, Prise en charge des personnes infectées par les virus de l'Hépatite B ou de l'Hépatite C

P. Cacoub, F. Dabis, D. Costagliola, K. Almeida, F. Lert et al., Burden of HIV and hepatitis C co-infection: the changing epidemiology of hepatitis C in HIV-infected patients in France, Liver International, vol.4, issue.27, pp.65-70, 2015.
DOI : 10.1111/liv.12639

. Available, invs.sante.fr/Dossiers-thematiques/Maladies- infectieuses/VIH-sida-IST/Donneurs-de-sang/La-surveillance-epidemiologique-des- donneurs-de-sang-VIH-VHC-VHB-HTLV-syphilis

J. Rockstroh, U. Spengler, D. Karageorgopoulos, A. J. Bhagani, and S. , HIV and hepatitic C virus co-infection Hepatitis C in human immunodeficiency virus co-infected individuals: Is this still a « special population, Lancet Infect Dis. World J Hepatol, vol.47, issue.13, pp.437-441936, 2004.

N. Terrault, J. Dodge, E. Murphy, J. Tavis, A. Kiss et al., Sexual transmission of hepatitis C virus among monogamous heterosexual couples: The HCV partners study, Hepatology, vol.32, issue.5 Suppl. 1, pp.881-889, 2013.
DOI : 10.1002/hep.26164

V. Tahan, C. Karaca, B. Yildirim, A. Bozbas, R. Ozaras et al., Sexual Transmission of HCV between Spouses, The American Journal of Gastroenterology, vol.2, issue.4, pp.821-824, 2005.
DOI : 10.1111/j.1572-0241.2004.04150.x

C. Vandelli, F. Renzo, L. Romano, S. Tisminetzky, D. Palma et al., Lack of Evidence of Sexual Transmission of Hepatitis C among Monogamous Couples: Results of a 10-Year Prospective Follow-Up Study, The American Journal of Gastroenterology, vol.20, issue.1, pp.855-859, 2004.
DOI : 10.1046/j.1440-1746.2000.02165.x

R. Browne, D. Asboe, Y. Gilleece, M. Atkins, S. Mandalia et al., Increased numbers of acute hepatitis C infections in HIV positive homosexual men; is sexual transmission feeding the increase? Sex Transm Infect Clinical présentation and course of acute hepatitis C infection in HIV-infected patients, The Hepatitis C epidemic among HIV-positive MSM: incidence estimates from, pp.326-333, 1990.

L. Mandelbrot, A. Berrebi, S. Matheron, S. Blanche, R. Tubiana et al., Infection par le VIH et grossesse??: nouvelles recommandations 2013??du groupe d???experts fran??ais, Journal de Gyn??cologie Obst??trique et Biologie de la Reproduction, vol.43, issue.7, pp.534-582, 2014.
DOI : 10.1016/j.jgyn.2014.01.006

M. Prasad and J. Honegger, Hepatitis C virus in pregnancy, Am J Perinatol, vol.30, pp.149-159, 2013.

C. Polis, S. Shah, K. Johnson, and A. Gupta, Impact of Maternal HIV Coinfection on the Vertical Transmission of Hepatitis C Virus: A Meta-analysis, Clinical Infectious Diseases, vol.44, issue.8, pp.1123-1131, 2007.
DOI : 10.1086/512815

S. Broutin, V. Bouton, M. Sinègre, and P. Marcellin, Anamnesis and diagnosis of hepatitis C, J Pharm Clin, vol.25, pp.49-56, 2006.

T. Poynard, V. Ratziu, C. F. Goodman, Z. Mchutchison, J. et al., Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection, Hepatol. J Hepatol, vol.3455, issue.28, pp.730-9245, 2001.

R. Westbrook and G. Dusheiko, Natural history of hepatitis C, Journal of Hepatology, vol.61, issue.1, pp.58-68, 2014.
DOI : 10.1016/j.jhep.2014.07.012

A. Freeman, G. Dore, M. Law, M. Thorpe, V. Overbeck et al., Estimating progression to cirrhosis in chronic hepatitis C virus infection, Hepatology, vol.34, issue.4, pp.809-825, 2001.
DOI : 10.1053/jhep.2001.27831

D. Dhumeaux, T. Morizane, T. Uchida, T. Yamagami, Y. Onozuka et al., Prise en charge des personnes infectées par les virus de l'Hépatite B ou de l'Hépatite C

D. Mitri, M. Poussin, K. Baccarini, P. Pontisso, P. et al., HCV-associated liver cancer without cirrhosis, The Lancet, vol.345, issue.8947, pp.413-418, 1995.
DOI : 10.1016/S0140-6736(95)90400-X

J. Chen, E. Feeney, and R. Chung, HCV and HIV co-infection: mechanisms and management, Nature Reviews Gastroenterology & Hepatology, vol.18, issue.6, pp.362-371, 2014.
DOI : 10.1038/nrgastro.2014.17

V. Dutoit, D. Ciuffreda, D. Comte, J. Gonvers, and G. Pantaleo, Differences in HCV-specific T cell responses between chronic HCV infection and HIV/HCV co-infection, European Journal of Immunology, vol.77, issue.12, pp.3493-3504, 2005.
DOI : 10.1002/eji.200535035

W. Lin, E. Weinberg, and R. Chung, Pathogenesis of Accelerated Fibrosis in HIV/HCV Co-infection, Journal of Infectious Diseases, vol.207, issue.suppl 1, pp.13-18, 2013.
DOI : 10.1093/infdis/jis926

D. Thomas, J. Astemborski, R. Rai, F. Anania, M. Schaeffer et al., The Natural History of Hepatitis C Virus Infection, JAMA, vol.284, issue.4
DOI : 10.1001/jama.284.4.450

P. Kokordelis, B. Kramer, C. Korner, C. Boesecke, E. Voigt et al., AN effective interféron-gamma-mediated inhibition of hepatitis C virus réplication by natural killer cells is associated with spontaneous clearance of acute hepatitis C in human immunodeficiency virus-positive patients Increasing hepatitis C virus RNA levels in hemophiliacs: Relationship to human immunodeficiency virus infection and liver disease, Hepatology. Blood, vol.5984, pp.814-8271020, 1994.

S. Gadalla, L. Preiss, M. Eyster, and J. Goedert, Correlates of high hepatitis C virus RNA load in a cohort of HIV-negative and HIV-positive individuals with haemophilia, Journal of Viral Hepatitis, vol.47, issue.7, pp.161-169, 2011.
DOI : 10.1111/j.1365-2893.2010.01289.x

Y. Benhamou, M. Bochet, D. Martino, V. , C. F. Azria et al., Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a metaanalysis, Hepatology. Clin Infect Dis, vol.3033, pp.1054-1062, 1999.

J. Cisneros, HIV coïnfection shortens the survival of patients with hepatitis C virusrelated decompensated cirrhosis, Hepatology, vol.41, pp.779-89, 2005.

N. Brau, R. Fox, X. P. Marks, K. Naqvi, Z. Taylor et al., Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A U.S.???Canadian multicenter study, Journal of Hepatology, vol.47, issue.4
DOI : 10.1016/j.jhep.2007.06.010

J. Orengo, Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antirétroviral therapy, J Hepatol, vol.44, pp.47-55, 2006.

A. Rivero, Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy, Hepatology, vol.46, pp.622-652, 2007.

H. Thein, Q. Yi, G. Dore, and M. Krahn, Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis, AIDS, vol.22, issue.15, pp.1979-91, 2008.
DOI : 10.1097/QAD.0b013e32830e6d51

F. In, The Mortavic 2010 study in collaboration with the Agence Nationale de Recherche sur le SIDA (ANRS) EN 20 Mortalité 2010 survey, HIV Med, vol.16, pp.230-239, 1995.

P. Ingiliz and J. Rockstroh, Natural history of liver disease and effect of hepatitis C virus on HIV disease progression, Current Opinion in HIV and AIDS, vol.10, issue.5, pp.303-308, 2015.
DOI : 10.1097/COH.0000000000000187

J. Rockstroh, A. Mocroft, V. Soriano, C. Tural, M. Losso et al., Influence of Hepatitis C Virus Infection on HIV???1 Disease Progression and Response to Highly Active Antiretroviral Therapy, The Journal of Infectious Diseases, vol.192, issue.6, pp.992-1002, 2005.
DOI : 10.1086/432762

L. Hua, J. Andersen, E. Daar, M. Glesby, K. Hollabaugh et al., Hepatitis C virus/HIV coïnfection and responses to initial antiretroviral treatment Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus Diagnostic discordance for hepatitis C virus infection in hemodialysis patients, AIDS. J Infect Dis. Am J Kidney Dis, vol.2720146, issue.57, pp.2725-2734823, 2005.

C. Thio, K. Nolt, J. Astemborski, D. Vlahov, K. Nelson et al., Screening for hepatitis C virus in human immunodeficiency virus-infected individuals, J Clin Microbiol, vol.38, pp.575-582, 2000.

E. Hadlich, A. Silva, M. , D. Molin, R. Zenker et al., Hepatitis C virus (HCV) viremia in HIV-infected patients without HCV antibodies détectable by thirdgeneration enzyme immunoassay, J Gastroenterol Hepatol, vol.9, pp.1506-1515, 2007.

L. Castera, M. Loko, L. Bail, B. Coffie, P. et al., Hepatic steatosis in HIV-HCV coinfected patients in France: comparison with HCV monoinfected patients matched for body mass index and HCV genotype, Alimentary Pharmacology & Therapeutics, vol.19, issue.11-12, pp.1489-98, 2007.
DOI : 10.1111/j.1365-2036.2007.03533.x

URL : https://hal.archives-ouvertes.fr/inserm-00177055

M. Konerman, S. Mehta, C. Sutcliffe, T. Vu, Y. Higgins et al., Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: Prospective analysis of 435 liver biopsy pairs, Hepatology, vol.1, issue.3, pp.767-75, 2014.
DOI : 10.1002/hep.26741

H. Kovari, B. Ledergerber, U. Peter, M. Flepp, J. Jost et al., Association of Noncirrhotic Portal Hypertension in HIV???Infected Persons and Antiretroviral Therapy with Didanosine: A Nested Case???Control Study, Clinical Infectious Diseases, vol.49, issue.4, pp.626-661, 2009.
DOI : 10.1086/603559

L. Castera, M. Winnock, E. Pambrun, V. Paradis, P. Perez et al., Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration, HIV Medicine, vol.50, issue.1 Pt 1, pp.30-39, 2014.
DOI : 10.1111/hiv.12082

V. De-lédinghen, C. Douvin, A. Kettaneh, M. Ziol, D. Roulot et al., Diagnosis of Hepatic Fibrosis and Cirrhosis by Transient Elastography in HIV/Hepatitis C Virus-Coinfected Patients, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.41, issue.2, pp.175-184, 2006.
DOI : 10.1097/01.qai.0000194238.15831.c7

P. Yeni, R. Chung, J. Andersen, P. Volberding, G. Robbins et al., Prise en charge médicale des personnes infectées par le VIH. Medecine- Sciences Flammarion ed, 2008.

A. Lazzarin, Peginterferon-alpha-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients, N Engl J Med, vol.351, pp.438-450, 2004.

C. Tural, J. Galeras, R. Planas, S. Coll, G. Sirera et al., Differences in virological response to pegylated interferon and ribavirine between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients, Antivir Ther, vol.13, pp.1047-55, 2008.

M. Sulkowski, S. Pol, J. Mallolas, H. Fainboim, C. Cooper et al., Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial, The Lancet Infectious Diseases, vol.13, issue.7, pp.597-605, 2013.
DOI : 10.1016/S1473-3099(13)70149-X

I. Jacobson, J. Mchutchison, G. Dusheiko, D. Bisceglie, A. Reddy et al., Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection, New England Journal of Medicine, vol.364, issue.25, pp.2405-2421, 2011.
DOI : 10.1056/NEJMoa1012912

L. Cotte, J. Braun, C. Lascoux-combe, C. Vincent, M. Valantin et al., Telaprevir for HIV/Hepatitis C Virus-Coinfected Patients Failing Treatment With Pegylated Interferon/Ribavirin (ANRS HC26 TelapreVIH): An Open-Label, Single-Arm, Phase 2 Trial, Clinical Infectious Diseases, vol.59, issue.12, p.trial
DOI : 10.1093/cid/ciu659

URL : https://hal.archives-ouvertes.fr/hal-01118447

I. Poizot-martin, E. Belissant, and P. Colson, Bocepreprevir for previously treated HCV-HIV coinfected patients: The ANRS-HC27 BocepreVIH Trial Triple therapy with boceprevir or telaprevir in European cohort of cirrhotic HIV/HCV génotype 1-coinfected patients, Conference on Retroviruses and Opportunistic Infections Liver Int, vol.35, pp.2090-2099, 2014.

L. Beste, P. Green, and G. Ioannou, Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients, European Journal of Gastroenterology & Hepatology, vol.27, issue.2, pp.123-132, 2015.
DOI : 10.1097/MEG.0000000000000241

C. Arvieux, M. Bourlière, P. Cacoub, P. Halfon, and K. Lacombe, Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver Use of first-generation HCV protéase inhibitors in patients coinfected by HIV and HCV genotype 1, Liver Int. Liver Int, vol.3234, issue.84, pp.1477-92869, 2012.

R. Bartenschlager, V. Lohmann, and F. Penin, The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection, Nature Reviews Microbiology, vol.90, issue.7, pp.482-96, 2013.
DOI : 10.1038/nrmicro3046

URL : https://hal.archives-ouvertes.fr/hal-00972320

D. Dieterich, J. Rockstroh, C. Orkin, F. Gutierrez, M. Klein et al., Simeprevir (TMC435) With Pegylated Interferon/Ribavirin in Patients Coinfected With HCV Genotype 1 and HIV-1: A Phase 3 Study, Clinical Infectious Diseases, vol.59, issue.11, pp.1579-87, 2014.
DOI : 10.1093/cid/ciu675

J. Molina, C. Orkin, D. Iser, F. Zamora, M. Nelson et al., Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study, The Lancet, vol.385, issue.9973, pp.1098-106, 2015.
DOI : 10.1016/S0140-6736(14)62483-1

A. Osinusi, K. Townsend, A. Kohli, A. Nelson, C. Seamon et al., Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection, JAMA, vol.313, issue.12, pp.1232-1241, 2015.
DOI : 10.1001/jama.2015.1373

M. Sulkowski, C. Hezode, J. Gerstoft, J. Vierling, J. Mallolas et al., Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial, The Lancet, vol.385, issue.9973, pp.1087-97, 2015.
DOI : 10.1016/S0140-6736(14)61793-1

S. Naggie, C. Cooper, M. Saag, K. Workowski, P. Ruane et al., Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1, New England Journal of Medicine, vol.373, issue.8, pp.705-718, 2015.
DOI : 10.1056/NEJMoa1501315

M. Sulkowski, J. Eron, D. Wyles, R. Trinh, J. Lalezari et al., Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1, JAMA, vol.313, issue.12, pp.1223-1254, 2015.
DOI : 10.1001/jama.2015.1328

J. Rockstroh, M. Nelson, C. Katlama, J. Lalezari, J. Mallolas et al., Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial, The Lancet HIV, vol.2, issue.8, pp.319-346, 2015.
DOI : 10.1016/S2352-3018(15)00114-9

S. Saeed, E. Strumpf, S. Walmsley, K. Rollet-kurhajec, N. Pick et al., How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?, Clinical Infectious Diseases, vol.62, issue.7, pp.919-945, 2016.
DOI : 10.1093/cid/civ1222

K. Lacombe, H. Fontaine, C. Dhiver, E. Rosenthal, S. Metivier et al., Daclatasvir plus Sofosbuvir with or without ribavirin in patients with HIV-HCV coinfection: intérim analysis of a French multicenter compassoinate use program. 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 2015.

S. Christensen, S. Mauss, D. Hueppe, K. Schewe, T. Lutz et al., Directly acting agents against HCV -Results from the GErman hepatitis C COhort (GECCO), 2016.

D. Dieterich, B. Bacon, S. Flamm, K. Kowdley, S. Milligan et al., P0775 : Final evaluation of 955 HCV patients treated with 12 week regimens containing sofosbuvir +/- simeprevir in the trio network: Academic and community treatment of a real-world, heterogeneous population, Journal of Hepatology, vol.62, p.621, 2015.
DOI : 10.1016/S0168-8278(15)30978-8

S. Pol, M. Bourlière, S. Lucier, V. De-ledinghen, F. Zoulim et al., LO3 : Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the french observational cohort ANRS CO22 hepather*, Journal of Hepatology, vol.62, p.258, 2015.
DOI : 10.1016/S0168-8278(15)30149-5

URL : https://hal.archives-ouvertes.fr/hal-01162711

O. El-sherif, S. Khoo, and C. Solas, Key drug???drug interactions with direct-acting antiviral in HIV???HCV coinfection, Current Opinion in HIV and AIDS, vol.10, issue.5, pp.348-54, 2015.
DOI : 10.1097/COH.0000000000000185

H. Bhatia, H. Singh, N. Grewal, and N. Natt, Sofosbuvir: A novel treatment option for chronic hepatitis C infection, J Pharmacol Pharmacother, vol.5, pp.278-84, 2014.

O. El-sherif, S. Khoo, and C. Solas, Key drug???drug interactions with direct-acting antiviral in HIV???HCV coinfection, Current Opinion in HIV and AIDS, vol.10, issue.5, pp.348-354, 2015.
DOI : 10.1097/COH.0000000000000185

G. Peytavin and C. Solas, Synthèse des interactions entre traitements antiretroviral et anti-VHC. Actualisation décembre 2015, 2016.

M. Bifano, C. Hwang, B. Oosterhuis, J. Hartstra, D. Grasela et al., Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir., Antiviral Therapy, vol.18, issue.7, pp.931-940, 2013.
DOI : 10.3851/IMP2674

P. German, K. Garrison, and P. Pang, Drug interactions between the anti-HCV regimen Ledipasvir

M. Andreoni, Exviera and Viekirax Combination Treatment in co-infected HIV- HCV patients: preliminary results of a Compassionate Use program. Italian Society for Tropical Medecine and Infectious Diseases, pp.9-11, 2015.